A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRI
R-Pharm
R-Pharm
Astellas Pharma Inc
Vanderbilt-Ingram Cancer Center
Amgen
Vanderbilt-Ingram Cancer Center
Erasca, Inc.
Amgen
Erasca, Inc.
MapKure, LLC
Biosplice Therapeutics, Inc.
Stanford University
Glycotope GmbH
Duke University
Duke University
UNC Lineberger Comprehensive Cancer Center
Massachusetts General Hospital
University of Utah
Amgen
Amgen
Duke University
University of Utah
Amgen
Jonsson Comprehensive Cancer Center
Amgen
Amgen